325P Real-world cabazitaxel survival to inform phase III development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC). // ESMO Real World Data and Digital Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949820126005072?dgcid=rss_sd_all
325P Real-world cabazitaxel survival to inform phase III development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC). ESMO Real World Data and Digital Oncology. https://www.sciencedirect.com/science/article/pii/S2949820126005072?dgcid=rss_sd_all
“325P Real-world cabazitaxel survival to inform phase III development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC).” ESMO Real World Data and Digital Oncology.
@article{article116746,
title = {325P Real-world cabazitaxel survival to inform phase III development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC)},
journal = {ESMO Real World Data and Digital Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949820126005072?dgcid=rss_sd_all}
}